Фармакологические свойства петлевых диуретиков и их клинические эффекты
Аннотация
Об авторах
Г. . Сакалаускене
Литовский университет наук здоровья
Россия
Россия
Г. . Цивинскене
Литовский университет наук здоровья
Россия
Россия
А. . Антушевас
Литовский университет наук здоровья
Россия
Россия
П. . Цивинскас
Литовский университет наук здоровья
Россия
Россия
Список литературы
1. Ernst M. E., Gordon J. A. Diuretic therapy: key aspects in hypertension and renal diseases. J. Nephrol 2010; 23 (5): 487-493.
2. Ernst M. E., Mann S.J. Diuretics in the Treatment of Hypertension. Semin Nephrol 2011; 31 (11): 495-502.
3. Sica D. A., Carter B., Cushman W., Hamm L. Thiazide and loop diuretics. J. Clin Hypertens 2011; 13 (9): 639-643.
4. Leto L., Aspromonte N., Feola M. Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Fail Rev 2014; 19 (2): 237-246.
5. Chiong J. R., Cheung R.J. Loop Diuretic Therapy in Heart Failure: The need for Solid Evidence on a Fluid Issue. Clin Cardiol 2010; 33 (6): 345-352.
6. Sica D. A. Diuretic use in renal disease. Nat Rev Nephrol 2011; 8 (2): 100-109.
7. Cox Z. L., Lenihan D.J. Loop Diuretic Resistance in Heart Failure: Resistance Etiology Based Strategies to Restoring Diuretic Efficacy. J. Cardiac Fail 2014; 20: 611-622.
8. Преображенский Д. В., Некрасова Н. И., Хосева Е.Н. и др. Торасемид - эффективный петлевой диуретик для длительной терапии артериальной гипертензии. Кардиология 2011; 4: 67-73.
9. Евдокимова А. Г., Коваленко Е. В., Евдокимов В. В., Ложкина М.В. Возможности применения торасемида в клинической практике. Кардиология 2011; 4: 67-73
10. Felker G. M., Menz R.J. Acute Decompensated Heart Failure. JACC 2012; 59 (24): 2145-2153.
11. Buggey J., Mentz R. J., Pitt B. et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015; 169: 323-333.
12. Felker G. M., Menz R.J., Shankar S. S., Brater D. K. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J. Physiol Renal Physiol 2003; 284: F11 - F21.
13. Roush G. S., Kaur R., Ernst M. E. Diuretics: A Rewiew and Update. J. Cardiovasc Pharmacol Ther 2014; 19 (1): 5-13.
14. Subramanya A. R., Elisson D. H. Diuretic Therapy. In: Core Concepts in the Disorders of Fluid, Electrolytes and Acid-Base Balance 2013; 171-201.
15. Wilcox C. S. New Insights into Diuretic Use in patients with Chronic Renal Disease. J. Am Soc Nephrol 2002; 13: 798-805.
16. Felker G. M. Diuretic management in Heart failure. Congest Heart Fail 2010; 16 (4): S68 - S72.
17. De Bruyne L. K. M. Mechanism and management of diuretic resistance in congestive heart failure. Postgrad Med J. 2003; 79: 268-271.
18. Felker G. M. Loop diuretics in heart failure. Heart Fail Rev 2012; 17: 305-311.
19. Buerkert J., Martin D., Prasad J. et al. Response of deep nephrons and the terminal collecting duct to a reduction in renal mass. Am J. Physiol 1979; 236: F454-F464.
20. Dargie H. J., Allison M. E., Kennedy A. C., Gray M. J. High dosage metolazone in chronic renal failure. Br Med J. 1972; 4: 196-198.
21. Lowenthal D. T., Dickermann D. The use of diuretics in varying degrees of renal impairment: An overview. Clin Exp Hypertens 1983; A5: 297-307.
22. Koomans H. A., Roos J. C., Boer P. et al. Salt sensitivity of blood pressure in chronic renal failure: evidence for renal control of body fluid distribution in man. Hypertension 1982; 4: 190-197.
23. Wollam G. L., Tarazi R. C., Bravo E. L., Dustan H. P. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J. Med 1982; 72: 929-938.
24. Brunner G., Von Bergmann K., Häcker W., Von Möllendorf E. Comparison of diuretic effects and pharmacokineticks of toresamide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzneim-Forsh Drug Res 1998; 38: 176-179.
25. Pichette V., du Souich P. Role of kidneys inb the metabolism of furosemide: its inhibition by probenicid. J. Am Soc Nephrol 1996; 7: 345-349.
26. Humes H. D. Insights into ototoxicity. Analogies to nephrotoxicity. Ann NY Acad Sci 1999; 884: 15-18.
27. Shankar S. S., Brater C. D. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003; 284: F11-F21.
28. Jutabha P., Anzai N., Wempe M. F. et al. Apical voltage - driven urate efflux transporter NPT4 in renal proximal tubule. Nucleosides, Nucleotides and Nucleic Acids 2010; 30: 1302-1311.
29. Rahman M., Pressel S., Davis B. R. et al. Cardiovascular outcomes in high-risk hypertensive patiens stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: 172-180.
30. Calhoun D. A., Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 54: 1403-1419.
31. Sica D. A. The risks and benefits of aldosterone antagonists. Curr Heart Fail Rep 2005; 2: 65-71.
32. Powers D. A., Duggan J., Brady H. R. Renal-dose (low-dose) dopamine for treatment of sepsis-related and other forms of acute renal failure: ineffecxtive and probably dangerous. Clin Exp Pharmacol Physiol 1999; 26: 523-528.
33. Vargo D. L., Brater D. C., Rudy D. W., Swan S. K. Dopamine does not enhance furosemide - induced natriuresis in patioents with congestive heart failure. J Am Soc Nephrol 1996; 7: 1032-1037.
34. Welch W.J. Adenosine, type I receptors: role in proximal tubule Na+ reabsorption. Acta Physiol (Oxf) 2015; 213 (1): 242-248.
35. Sica D. A., Gehr T. W. Diuretic use in stage five chronic kidney disease and end - stage renal disease. Curr Opin Nephrol Hypertens 2003; 12: 483-490.
36. Bragg-Gresham J. L., Fissell R. B., Mason N. A. et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and practice Pattern Study (DOPPS). Am J Kidney Dis 2007; 49: 426-431.
37. Stamatakis M. K. Treatment and prevention of acute renal failure. J Pharm Pract 2002; 15 (5): 392-404.
38. Brater D. C. Pharmacology of diuretics. AmJ Med Sci 2000; 319: 38-50.
39. Schetz M. Should we use diuretics in acute renal failure? Best practice & research. Clin Anaestheosiol 2004; 18 (1): 75-89.
40. Piccinni P., Gramaticopolo S. Diuretics in Intensive Care: Positive and Negative Aspects. In Allaria B., eds. Practical Issues in Anesthesia and Intensive Care. Milan: Springer-Verlag Italia; 2012: 59-71.
41. Bonegio R., Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Cur Opinion Nephrol Hypertens 2002; 11: 301-308.
42. Denton M. D., Chertow G. M., Brady H. R. “Renal dose" dopamine-for the treatment of acute renal failure: scientific rationale, experi-mentalstudies and clinical trials. Kidney Int 1996; 49: 1-4.
43. Mathur V. S., Swan S. K., Lambrecht L. J. et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27: 1832-1837.
44. Lewis J., Salem M. M., Chertow G. M. et al. Atrial natriuretic factor in oliguric acute renal failure. Am J Kidney Dis 2000; 36: 767-774.
45. Kellum J. A., Mehta R. L., Ronco C. Acute dialysis quality initiative (ADQI). Contrib Nephrol 2001; 132: 258-265.
46. Hull R. P., Goldsmith D. A. J. Nephrotic syndrome in adults. BMJ 2008; 336: 1185-1189.
47. Ghafari A.,Mehdizadeh A., Alavi-Darazam I. et al. Co-administration of Albumin-Furosemide in Patients with the Nephrotic Syndrome. Saudi J Kidney Dis Transpl 2011; 22 (3): 471-475.
48. Kodner C. Nephrotic Syndrome in Adults: Diagnosis and Management. Am Fam Physician 2009; 80 (10): 1129-1134.
49. Brater D. C. Diuretic therapy. N Engl J Med 1998; 339: 229-395.
50. Agarwal R., Gorski J., Sundblad K., Brater D. C. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 2000; 11: 1100-1105.
51. Esnault V. L., Erhlas A., Delcroix C., Moutel M. G., Nguyen J. M. Diuretic and enhanced sodium restriction results in improved anti-proteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 1 №5: 4-7 4-481.
52. Kunz R., Friedrich C., Wolbers M., Mann J. F. Meta-analysis: effect of monotherapy and combination therapy of renin-angiotensin system on proteinuria in renal diseases. Ann Intern Med 2008; 148: 30-48.
Рецензия
Для цитирования:
Сакалаускене Г..., Цивинскене Г..., Антушевас А..., Цивинскас П... Фармакологические свойства петлевых диуретиков и их клинические эффекты. Кардиология. 2018;58(1):72-83. https://doi.org/10.18087/cardio.2018.1.10084
For citation:
Sakalauskienè G..., Civinskienè G..., Antusevas A..., Civinskas P... Pharmacological Properties of Loop Diuretics and Their Clinical Effects. Kardiologiia. 2018;58(1):72-83. (In Russ.) https://doi.org/10.18087/cardio.2018.1.10084
Просмотров: 1836
Послать статью по эл. почте 
Оставить комментарий 